How to Reconstitute MK-677 (Ibutamoren): Storage, Stability, and Dosing After Mixing

What Is MK-677 and Why Does Reconstitution Matter?

MK-677 (Ibutamoren) is a non-peptide ghrelin receptor agonist that stimulates growth hormone secretion. It is not a classic peptide, but it is frequently compounded and dispensed in lyophilized powder form for subcutaneous use, which means you need to reconstitute it correctly before every use cycle.

Getting the reconstitution step wrong does not just waste an expensive vial. Incorrect dilution alters your dose with every draw. Using the wrong diluent can degrade the compound within days rather than weeks. And improper storage after mixing introduces microbial contamination risk that standard refrigeration alone cannot fully eliminate.

For women specifically, dosing precision matters more than most online guides acknowledge. Your body weight, hormonal status, and metabolic baseline all change the pharmacodynamic response to a growth hormone secretagogue. A 55 kg woman in perimenopause with early insulin resistance has a very different risk profile from a 75 kg woman in her reproductive years using MK-677 off-label for body composition. The reconstitution process is the foundation of dose accuracy, so it deserves more than a three-sentence tutorial.

MK-677 Is Not Approved by the FDA

The FDA has not approved MK-677 for any indication in humans. The FDA classifies ibutamoren as an investigational drug, and it has been removed from dietary supplement eligibility. Compounded injectable preparations exist in a gray-market space. This article covers reconstitution technique for harm reduction purposes. WomanRx does not prescribe or endorse off-label use outside a supervised clinical relationship.

Pregnancy and Lactation Safety: Read This First

MK-677 is contraindicated in pregnancy. This is not a theoretical caution. Ghrelin receptor agonism modifies IGF-1 and growth hormone axis signaling, both of which are tightly regulated during fetal development. Supraphysiologic IGF-1 elevation during pregnancy is associated with adverse fetal and placental outcomes, and no human safety data exists for ibutamoren in pregnant women.

Lactation

No data exists on MK-677 transfer into human breast milk. Given its mechanism of action and the sensitivity of neonatal GH-axis development, use during breastfeeding carries an unquantified but real risk. Until transfer studies are published, the prudent clinical position is to avoid MK-677 entirely during lactation.

Contraception Requirement

If you are of reproductive age and using MK-677, you should use reliable contraception throughout the course and for at least one full cycle after stopping. A barrier method combined with hormonal contraception is the most conservative approach. ACOG advises that investigational agents with unknown fetal risk profiles require documented contraception counseling before prescribing.

Trying to Conceive

Stop MK-677 at least one full menstrual cycle before attempting conception. The wash-out kinetics of ibutamoren are not well characterized in women, but its half-life of approximately 24 hours suggests systemic clearance within five to seven days. The precautionary cycle-length buffer accounts for lingering IGF-1 elevation.

The Standard Reconstitution Protocol for MK-677

The core answer: add 1-2 mL of bacteriostatic water to a 10 mg or 25 mg vial of lyophilized MK-677. Use a slow, wall-directed injection of the diluent. Never shake. Let the powder dissolve by gentle swirling.

Step-by-Step Reconstitution

What you need before you start:

• Lyophilized MK-677 vial (typically 10 mg or 25 mg)
• Bacteriostatic water for injection (9 mg/mL benzyl alcohol, USP grade)
• Two alcohol swabs (70% isopropyl)
• One 1 mL or 3 mL sterile luer-lock syringe for drawing diluent
• One 18-21 gauge needle for drawing and injecting diluent into vial
• Insulin syringes (U-100, 29-31 gauge, 0.5 mL or 1 mL) for dosing draws

Step 1: Clean the vial tops. Swab the rubber septum of both the bacteriostatic water vial and the MK-677 vial with a fresh alcohol swab. Allow 30 seconds to dry completely.

Step 2: Draw bacteriostatic water. Using your larger syringe and 18-21 gauge needle, draw the calculated volume of bacteriostatic water. For a 10 mg vial, draw 1 mL. For a 25 mg vial, draw 2 mL. These volumes yield clean round concentrations (10 mg/mL and 12.5 mg/mL respectively) that simplify dosing math.

Step 3: Inject at the vial wall, not directly onto the powder. Angle the needle so the stream of bacteriostatic water runs down the inside glass wall before reaching the lyophilized cake. This prevents foaming and mechanical degradation of the compound. USP General Chapter 797 standards for sterile compounding require gentle reconstitution to preserve structural integrity of lyophilized compounds.

Step 4: Do not shake. Once diluent is added, gently roll or swirl the vial. The powder should dissolve within 30-60 seconds to yield a clear, colorless solution. If the solution is cloudy or contains visible particulate after two minutes of gentle swirling, do not use the vial.

Step 5: Label immediately. Write the reconstitution date and discard-by date (28 days from today) directly on the vial with a permanent marker. Store in the refrigerator.

How Much Bacteriostatic Water to Use: The Concentration Calculator

The volume of bacteriostatic water you add determines your final concentration, which in turn determines how many units on your insulin syringe equal one dose. Getting this wrong by even 0.1 mL shifts every subsequent dose.

Standard Concentration Reference Table

| Vial Size | Bacteriostatic Water Added | Final Concentration | Volume per 10 mg dose | |-----------|---------------------------|---------------------|-----------------------| | 10 mg | 1 mL | 10 mg/mL | 0.1 mL (10 units on U-100) | | 10 mg | 2 mL | 5 mg/mL | 0.2 mL (20 units on U-100) | | 25 mg | 2 mL | 12.5 mg/mL | 0.08 mL (8 units on U-100) | | 25 mg | 2.5 mL | 10 mg/mL | 0.1 mL (10 units on U-100) |

The 10 mg/mL concentration (1 mL into a 10 mg vial, or 2.5 mL into a 25 mg vial) is the easiest to work with because each 10 units on a U-100 insulin syringe delivers exactly 1 mg. For women starting at a low dose of 5 mg, that is 5 units. Clean, easy math reduces dosing error.

Why Bacteriostatic Water and Not Sterile Water?

Bacteriostatic water contains 0.9% benzyl alcohol as a preservative. This is what gives it multi-dose safety. Benzyl alcohol at 9 mg/mL inhibits bacterial growth and allows the reconstituted vial to remain usable across multiple draws over 28 days without contamination from repeated needle punctures.

Sterile water for injection (SWFI) contains no preservative. If you reconstitute with SWFI, you must treat the vial as single-use and discard within 24 hours, refrigerated. For any multi-dose regimen, bacteriostatic water is the correct choice.

The WomanRx Diluent Decision Framework:

Use bacteriostatic water if:

• You are drawing multiple doses from one vial over days to weeks
• Your prescribed regimen runs longer than three days
• You are storing the reconstituted vial in the refrigerator

Use sterile water only if:

• You have a documented benzyl alcohol allergy (rare but real)
• You are using the entire vial in a single session
• Your compounding pharmacy has specifically directed single-use preparation

Women with benzyl alcohol sensitivity should discuss alternative diluents with their prescriber before reconstituting.

Storage and Stability After Mixing: What the Data Shows

Lyophilized MK-677 is stable at room temperature for months when stored dry and away from light. Once reconstituted, the compound's stability window narrows significantly.

Refrigerated Storage (2-8°C)

Reconstituted MK-677 solution maintains concentration and sterility for up to 28 days when refrigerated. This 28-day window is derived from USP Chapter 797 standards for multi-dose containers reconstituted with bacteriostatic preservative, not from compound-specific stability studies on ibutamoren, which do not currently exist in peer-reviewed literature. The practical implication: treat your vial conservatively. If the solution has been sitting for 25 days, discard and reconstitute fresh.

Freezing Reconstituted Solution: Not Recommended

Freezing a reconstituted peptide vial risks ice crystal formation that damages the compound's molecular structure. For true peptides (growth hormone releasing hormones, for example), this is well documented. MK-677 is technically a non-peptide small molecule, but the benzyl alcohol preservative also loses bacteriostatic efficacy through freeze-thaw cycling. Keep the reconstituted vial in the refrigerator body, not the door (temperature swings) and not the freezer.

Light and Temperature Exposure

UV light degrades many GH secretagogue compounds. Store the vial in its original box or wrapped in foil inside the refrigerator. Photodegradation of growth hormone-related peptides has been documented in stability studies, and although this specific data applies to peptide GHRHs, the precaution is reasonable for any light-sensitive compound in solution.

If your vial has been left at room temperature for more than four hours (for example, during travel), it is not automatically ruined, but cumulative room-temperature exposure shortens effective stability. Track total time out of refrigeration across the vial's life.

Signs a Reconstituted Vial Should Be Discarded

• Visible cloudiness or particulate that does not clear with gentle swirling
• Color change from clear to yellow or amber
• Visible flakes or precipitate
• Any vial that has been punctured more than 30 times (septum integrity)
• Any vial past its 28-day discard date

Drawing and Injecting with an Insulin Syringe

For subcutaneous MK-677, the insulin syringe is the standard tool. A U-100 syringe holds 1 mL of fluid and is graduated in 1-unit (0.01 mL) increments. The fine needle gauge (29-31 gauge) makes subcutaneous injections nearly painless compared to larger bore needles.

Reading the Syringe Correctly

A U-100 syringe labels doses in units, not milligrams or milliliters. The relationship between units and volume is fixed: 100 units = 1 mL. So 10 units = 0.1 mL, 50 units = 0.5 mL.

Once you know your vial concentration (see the table above), the math is:

Units to draw = (Dose in mg / Concentration in mg per mL) x 100

Example: You want 10 mg from a vial reconstituted to 10 mg/mL. (10 / 10) x 100 = 10 units on the syringe.

Example: You want 5 mg from a vial reconstituted to 12.5 mg/mL. (5 / 12.5) x 100 = 40 units on the syringe.

Write this out for your specific vial before every new reconstitution. Recalculate if you use a different water volume.

Subcutaneous Injection Technique

1. Remove the MK-677 vial from the refrigerator 10-15 minutes before injecting to allow it to reach room temperature. Cold solution stings more at the injection site.
2. Swab the vial septum with a fresh alcohol swab.
3. Draw your calculated volume.
4. Common injection sites for women: lower abdomen (at least 5 cm from the navel), lateral thigh, or upper lateral buttock. Rotate sites to avoid lipohypertrophy.
5. Pinch a skin fold, insert the needle at a 45-90 degree angle depending on your subcutaneous fat layer, and inject slowly.
6. Apply light pressure with a clean gauze after withdrawal. Do not rub.

Women-Specific Dosing Considerations by Life Stage

MK-677's effect on IGF-1 and growth hormone is not uniform across hormonal contexts. The studies most cited for MK-677 dosing were conducted in older male populations or mixed-sex cohorts skewed male. The landmark Copinschi et al. 1997 study in the JCEM used a predominantly male cohort to establish the 25 mg/day dose-response curve for ibutamoren. Women were under-represented and subgroup data were not sex-stratified.

Reproductive Years (Ages 18-40)

Women in the reproductive years have higher endogenous GH pulse amplitude than men of similar age, particularly in the late follicular phase. Sex-based differences in GH secretion show women secrete approximately twice the daily GH of age-matched men under normal conditions. Adding a GH secretagogue on top of already-higher baseline pulsatility may amplify IGF-1 elevation more than expected from male-derived dosing tables.

Starting at 10 mg rather than 25 mg is a reasonable precaution. IGF-1 should be checked at baseline and after four weeks.

Perimenopause (Ages ~42-52)

Estrogen decline reduces GH pulse amplitude. Some women and their clinicians consider GH secretagogues for this reason, targeting improved sleep architecture, lean mass preservation, and metabolic support. The evidence base for this specific use is thin. A 2020 review in Menopause found no adequately powered RCTs of GH secretagogues specifically in perimenopausal women, though observational data on GH replacement in menopause is more developed.

Perimenopausal women with insulin resistance or early metabolic syndrome need blood glucose monitoring before and during use. MK-677 acutely reduces insulin sensitivity in clinical studies.

PCOS

Women with polycystic ovary syndrome frequently have elevated baseline IGF-1 and insulin resistance. IGF-1 amplifies androgen production in theca cells, which means adding a compound that further elevates IGF-1 may worsen hyperandrogenism, acne, or hirsutism. If you have PCOS, discuss this risk explicitly with your prescriber before reconstituting your first vial.

Post-Menopause

Post-menopausal women have the lowest endogenous GH pulsatility of any female life stage. The GH secretagogue effect is proportionally larger in this context. Fluid retention (a common MK-677 side effect) compounds with post-menopausal cardiovascular risk factors. Start low, monitor blood pressure and fasting glucose, and do not combine with corticosteroids or other insulin-sensitizing drugs without medical supervision.

Evidence Gaps and Honest Limitations

Most published MK-677 human data comes from four settings: elderly men with muscle wasting, adults with GH deficiency, obese adults for metabolic endpoints, and healthy young men for GH kinetics. Women are systematically under-represented.

The GHRP-2 and ibutamoren literature reviewed in a 2021 Frontiers in Endocrinology meta-analysis did not include a single trial enrolling only female participants. Dosing recommendations on women-focused wellness sites are almost entirely extrapolated from male data or from anecdotal compounding pharmacy protocols.

This is not a reason to dismiss MK-677 entirely if you are considering it under clinical supervision. This is a reason to start at the lowest reasonable dose, track IGF-1 and fasting glucose, and not assume the "standard" 25 mg dose applies to your body.

Who This Protocol Is Right For and Who Should Avoid It

This reconstitution guide applies if you:

• Have received a compounded injectable MK-677 preparation from a licensed 503A or 503B compounding pharmacy
• Are under active clinical supervision with baseline labs (IGF-1, fasting glucose, CBC)
• Are not pregnant, breastfeeding, or attempting to conceive
• Are not diagnosed with active malignancy (GH secretagogues are contraindicated with any active neoplastic disease)

Avoid reconstituted injectable MK-677 if you:

• Are pregnant or trying to conceive within one menstrual cycle
• Have PCOS with uncontrolled hyperandrogenism or insulin resistance above HOMA-IR 3.5
• Have a history of any hormone-sensitive cancer
• Have untreated hypothyroidism (MK-677 may suppress T4 conversion via IGF-1 feedback)
• Have a known benzyl alcohol hypersensitivity and cannot access alternative diluents

Women with type 2 diabetes or prediabetes should not use MK-677 without endocrinology co-management. Clinical trials of ibutamoren documented fasting glucose increases of 5-8 mg/dL at 25 mg/day in metabolically healthy adults. In women with baseline glucose dysregulation, that effect is likely amplified.

Monitoring While Using Reconstituted MK-677

At minimum, check these labs before starting and at four-week intervals:

• IGF-1 (target: mid-to-upper normal range for your age, not supraphysiologic)
• Fasting glucose and insulin (calculate HOMA-IR)
• TSH and free T4 (MK-677 may suppress T4)
• Complete metabolic panel (for fluid and electrolyte status)

Women in perimenopause or post-menopause should add a blood pressure check at each visit. Fluid retention from MK-677 can push borderline blood pressure into the hypertensive range within weeks.